Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Abstract
Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondria, too, are damaged by oxidative and nitrosative stress in AD as noted [34].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of Aβ oligomers in mitochondrial membranes is consistent with Aβ-induced mitochondrial dysfunction occurring early in the disease progression timeline [34,53].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Oxidative stress from mitochondrial dysfunction and reactive oxygen species (ROS) accumulation further heightens neuronal vulnerability [6].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“plaques may arguably have AD; a current construct refers to this state as “preclinical AD” [144].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Due to the presence of the mutated mtPOLG transgene, these mice acquire excess somatic mtDNA mutations and mitochondrial dysfunction [65, 66].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundBloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“In response to this, some now speculate A itself is insufficient to cause the disease, but instead initiates AD by triggering a critical change in tau biology [114, 119, 120].”
Background
Research works printed but not linked: 1
- Parker WD (1990) Sporadic neurologic disease and the electron transport chain: A hyothesis In Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease, Pascuzzi RM, ed. Indiana University Printing Services, Bloomington, Indiana.
Cited by
Items 301–400 of 856
Chen, G., Su, Y. A., Chen, S., Lin, T., & Lin, X. (2025) · Food Science & Nutrition · doi:10.1002/fsn3.70496 · Cited by 36
Navigating Alzheimer’s Disease via Chronic Stress: The Role of Glucocorticoids
Sharma, V., & Singh, T. G. (2019) · Current Drug Targets · doi:10.2174/1389450120666191017114735 · Cited by 26
Mitochondrial localization of NCXs: Balancing calcium and energy homeostasis
Magi, S., Piccirillo, S., Preziuso, A., Amoroso, S., & Lariccia, V. (2020) · Cell Calcium · doi:10.1016/j.ceca.2020.102162 · Cited by 26
Zhu, C., Zhang, Z., Zhu, Y., Du, Y., Han, C., Zhao, Q., Li, Q., Hou, J., Zhang, J., He, W., et al. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118859 · Cited by 41
Vishnumukkala, T., Nassir, C. M. N. C. M., Hein, Z. M., Gopalakrishna, P. K., Karikalan, B., Alkatiri, A., Jagadeesan, S., Naik, V. R., Thomas, W., Moklas, M. A. M., et al. (2025) · Cells · doi:10.3390/cells14191497 · Cited by 32
“Excessive ROS production damages lipids, proteins, and DNA, creating a vicious cycle involving oxidative stress and further mitochondrial damage [43].”
Clement, A., Wiborg, O., & Asuni, A. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00056 · Cited by 28
“The ‘‘mitochondrial cascade hypothesis’’ of sporadic AD postulate that mitochondrial dysfunction is the major cause of AD pathology and that Aβ accumulation is a secondary event (Swerdlow and Khan, 2004; Swerdlow et al., 2014; Swerdlow, 2018).”
BackgroundHeat therapy: possible benefits for cognitive function and the aging brain
Schulze, A. T. V., Deng, F., Morris, J. K., & Geiger, P. C. (2020) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00168.2020 · Cited by 29
“Decades of research indicates that mitochondria from subjects with AD differ from mitochondria from subjects without dementia or cognitive dysfunction (113).”
BackgroundXue, W., Li, J., Fu, K., & Teng, W. (2020) · BioMed Research International · doi:10.1155/2020/4505720 · Cited by 27
“Dysfunction of dynamics of mitochondria may present in the early stage of AD [38, 46], suggesting that mitochondria may become a potential target for the early treatment for AD [47].”
Guo, S., Ma, Y., Pan, Y., Smith, Z. J., & Chu, K. (2021) · Biomedical Optics Express · doi:10.1364/boe.425848 · Cited by 25
Russell, A. E., Jun, S., Sarkar, S., Geldenhuys, W. J., Lewis, S. E., Rellick, S. L., & Simpkins, J. W. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00051 · Cited by 28
“AD is characterized by neuroinflammation (Wyss-Coray and Rogers, 2012) and mitochondrial dysfunction (Swerdlow, 2018).”
BackgroundXie, W., Jiao, B., Bai, Q., Ильин, В. Н., Sun, M., Burton, C. E., Kolodieznyi, D., Calderon, M. J., Stolz, D. B., Opresko, P. L., et al. (2020) · eLife · doi:10.7554/elife.51845 · Cited by 28
“Alterations in neuronal mitochondrial function have been strongly linked to several neurodegenerative diseases (Nguyen et al., 2019; Swerdlow, 2018; Carmo et al., 2018) and there is significant interest in understanding how mitochondrial homeostasis and bioenergetics are maintained in neurons under…”
BackgroundEssa, H., Peyton, L., Hasan, W., León, B. E., & Choi, D. (2022) · Cells · doi:10.3390/cells11020286 · Cited by 28
Chen, H., Xing, H., Zhong, C., Lin, X., Chen, R., Luo, N., Chen, L., & Huang, Y. (2024) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlae010 · Cited by 24
Critical role of dysfunctional mitochondria and defective mitophagy in autism spectrum disorders
Wang, Y., Qiu, M.-Y., Liu, Q., Tang, H., & Gu, H. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.12.022 · Cited by 30
dos Santos, M. F., Roxo, C., & Solá, S. (2021) · Antioxidants · doi:10.3390/antiox10071088 · Cited by 26
“Further, Aβ directly interacts with mitochondria, resulting in impaired activity of complexes III and IV, reduced ATP production, mitochondrial calcium overload, disturbance of mitochondrial fusion and fission and increased generation of ROS [43,62].”
BackgroundMyricetin Restores Aβ-Induced Mitochondrial Impairments in N2a-SW Cells
Yao, X., Zhang, J., Lu, Y.-F., Deng, Y., Zhao, R., & Xiao, S. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00591 · Cited by 25
Duan, L., Hu, M., Tamm, J. A., Grinberg, Y. Y., Shen, F., Chai, Y., Xi, H. S., Gibilisco, L., Ravikumar, B., Gautam, V., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-82658-7 · Cited by 28
Mansour, H. E. A., Elberri, A. I., Ghoneim, M. E.-S., Samman, W. A., Alhaddad, A., Abdallah, M. S., Elberri, E. I., Salem, M. A., & Mosalam, E. M. (2023) · Molecules · doi:10.3390/molecules28186566 · Cited by 26
“A growing body of evidence suggested that dysregulation of MMP may occur due to oxidative stress and neuroinflammation [53,54].”
RetractedMitochondrial dysfunction and Alzheimer’s disease: pathogenesis of mitochondrial transfer
Wei, Y., Du, X., Guo, H., Han, J., & Liu, M. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1517965 · Cited by 26
Linkage of circadian rhythm disruptions with Alzheimer's disease and therapeutic interventions
Madhamanchi, K., Zhang, J., & Melkani, G. C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.04.011 · Cited by 30
“This leads to synaptic dysfunction, accelerating neuronal loss, and promoting cognitive decline 21 .”
Muguruma, Y., Tsutsui, H., Akatsu, H., & Inoue, K. (2019) · Biomedical Chromatography · doi:10.1002/bmc.4722 · Cited by 22
Avram, S., Mernea, M., Limban, C., Borcan, F., & Chifiriuc, M. C. (2019) · Current Neuropharmacology · doi:10.2174/1570159x18666191230120053 · Cited by 24
Qin, T., Prins, S., Groeneveld, G. J., van Westen, G. J. P., de Vries, H. E., Wong, Y. C., Bischoff, L. J. M., & de Lange, E. C. M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093158 · Cited by 27
“The contribution of mitochondria in the pathogenesis of AD has also been studied (which relates to oxidative stress); however, their exact role and place in the disease cascade is still not fully known [47].”
BackgroundYi, C., Goh, K. Y., Wong, L., Ramanujan, A., Tanaka, K., Sajikumar, S., & Ibáñez, C. F. (2020) · The EMBO Journal · doi:10.15252/embj.2020104450 · Cited by 24
TRPM2 channel in oxidative stress-induced mitochondrial dysfunction and apoptotic cell death
Malko, P., Ding, R., & Jiang, L. (2021) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2020.12.001 · Cited by 28
Mini review: Mitochondrial dysfunction in Alzheimer's disease: Therapeutic implications of lithium
Singulani, M. P., Paula, V. J. R. D., & Forlenza, O. V. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136078 · Cited by 26
Mitochondrial defects: An emerging theranostic avenue towards Alzheimer's associated dysregulations
Mani, S., Swargiary, G., Singh, M., Agarwal, S., Dey, A., Ojha, S. K., & Jha, N. K. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119985 · Cited by 26
Site-specific mitochondrial dysfunction in neurodegeneration
Vodičková, A., Koren, S. A., & Wojtovich, A. P. (2022) · Mitochondrion · doi:10.1016/j.mito.2022.02.004 · Cited by 23
Amyloid-β42 stimulated hippocampal lactate release is coupled to glutamate uptake
Hascup, E. R., Sime, L. N., Peck, M. R., & Hascup, K. N. (2022) · Scientific Reports · doi:10.1038/s41598-022-06637-2 · Cited by 25
Age-Dependent Behavioral and Metabolic Assessment of AppNL−G−F/NL−G−F Knock-in (KI) Mice
Wang, S., Ichinomiya, T., Savchenko, P., Devulapalli, S., Wang, D., Beltz, G., Saito, T., Saido, T. C., Wagner, S. L., Patel, H. H., et al. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.909989 · Cited by 23
“Abnormalities in mitochondrial dynamics are widely observed in the setting of neurodegenerative conditions, including Alzheimer’s disease and Parkinson’s disease (PD) (Zhu et al., 2006; Jones, 2010; Schapira and Patel, 2014; Swerdlow, 2018; Tyumentsev et al., 2018), while under normal cellular physiological conditions…”
BackgroundDifferent Effects and Mechanisms of Selenium Compounds in Improving Pathology in Alzheimer’s Disease
Zhang, Z., Peng, J., Chen, Y., Wang, C., Chen, C., & Song, G.-L. (2023) · Antioxidants · doi:10.3390/antiox12030702 · Cited by 27
Cáceres, C., Heusser, B., Garnham, A., & Moczko, E. (2023) · Cells · doi:10.3390/cells12232669 · Cited by 27
Shannon entropy approach reveals relevant genes in Alzheimer’s disease
Monaco, A., Amoroso, N., Bellantuono, L., Lella, E., Lombardi, A., Monda, A., Tateo, A., Bellotti, R., & Tangaro, S. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226190 · Cited by 24
“Abnormalities in cellular bioenergetics have been detected in a lot of people affected by AD and their links with dementia have been highlighted in several experiments in vivo and in vitro [69].”
BackgroundVolloch, V., Olsen, B. R., & Rits‐Volloch, S. (2019) · Annals of Integrative Molecular Medicine · doi:10.33597/aimm.02-1007 · Cited by 30
“This is the primary reason for the formulation of the Mitochondrial Cascade Hypothesis, MCH [13,14], but even in terms of the MCH, the core of the disease is the amyloid cascade as defined in the ACH [7– 12].”
MethodKim, S. H., Choi, K. Y., Park, Y., McLean, C., Park, J., Lee, J. H., Lee, K., Kim, B. C., Huh, Y. H., Lee, K. H., et al. (2021) · Cells · doi:10.3390/cells10102697 · Cited by 25
“Accumulated evidences indicate that mitochondrial dysfunction might be a primary factor in AD development [5,16,17].”
BackgroundSepúlveda-Lara, A., Sepúlveda, P., & Marzuca-Nassr, G. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137084 · Cited by 25
“The oxidative hypothesis, also called the mitochondrial cascade hypothesis (Figure 2 (c)), considers the mitochondrial function of neurons [42,43], specifically the oxygen requirements of the brain and how metabolic abnormalities could lead to AD [44,45].”
BackgroundSingh, S., & Singh, R. K. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-10297-6 · Cited by 25
“By investigating mitochondrial biogenesis, dynamics, interactions between the endoplasmic reticulum and mitochondria, axonal transport, mitophagy, and mitochondrial proteostasis, we aim to guide future therapeutic approaches for addressing AD [2].”
InfluentialGao, H., Jensen, K. N., Nesbitt, J. J., Ostroot, M., Cary, G. A., Wiley, J. C., Trushin, S., Watzlawik, J. O., Springer, W., Galkin, A. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70519 · Cited by 25
Xiao, X., Yan, X., Liang, C., & Yang, Y. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2026.1772036 · Cited by 27
“The impacts of several risk factors and biomarkers, including as tau hyperphosphorylation and A β elevation, may be caused by impaired neuroplasticity and mitochondrial dysfunction (97), which may be a common upstream etiology of AD.”
The Cardiac Dysfunction Caused by Metabolic Alterations in Alzheimer's Disease
Murphy, J., Le, T. N. V., Fedorova, J., Yang, Y., Krause‐Hauch, M., Davitt, K., Zoungrana, L. I., Fatmi, M. K., Lesnefsky, E. J., Li, J., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.850538 · Cited by 23
“Previous studies demonstrated that mitochondrial dysfunction is implicated in AD and cardiac dysfunction, in which a significant reduction of ATP production, as well as increased oxidative stress, were observed as a result of mitochondrial defect (32, 41).”
Critical appraisal on mitochondrial dysfunction in Alzheimer’s disease
Ahmad, F., & Sachdeva, P. (2022) · Aging Medicine · doi:10.1002/agm2.12217 · Cited by 23
Finney, C. A., Delerue, F., Gold, W. A., Brown, D. A., & Shvetcov, A. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.12.018 · Cited by 22
“Mitochondria are increasingly being shown to contribute to the development and progression of AD, with evidence for both primary and secondary dysfunctional mitochondrial cascades (for reviews see [42,43]).”
BackgroundThe gene expression patterns as surrogate indices of pH in the brain
Hagihara, H., Murano, T., & Miyakawa, T. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1151480 · Cited by 20
Tang, L., Wang, Y., Xiang, J., Yang, D., Zhang, Y., Qin, X., & Li, J. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12125 · Cited by 24
“In addition, the accumulation of mitochondrial superoxide free radicals and transformation to hydrogen peroxide can cause oxidative stress, the release of cytochrome C and apoptosis, which are also important mechanisms of AD (51).”
Kannan, H. T., Issac, P. K., Dey, N., Guru, A., & Arockiaraj, J. (2023) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-023-10558-7 · Cited by 24
Dienel, G. A. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2611-y · Cited by 21
Recent trends of natural based therapeutics for mitochondria targeting in Alzheimer’s disease
Dhiman, A., Handa, M., Ruwali, M., Singh, D. P., Kesharwani, P., & Shukla, R. (2022) · Mitochondrion · doi:10.1016/j.mito.2022.03.006 · Cited by 21
Zhang, W., Liu, D., Yuan, M., & Zhu, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102307 · Cited by 30
Mitochondrial DNA abundance in blood is associated with Alzheimer’s disease- and dementia-risk
Stocker, H. R., Gentiluomo, M., Trares, K., Beyer, L., Stevenson‐Hoare, J. O., Rujescu, D., Holleczek, B., Beyreuther, K. T., Gerwert, K. B., Schöttker, B., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02670-x · Cited by 24
“[30] mtDNAcn may however capture pathophysiological processes independent of the biomarkers, P-tau181, GFAP, and NfL.”
O-GlcNAc impacts mitophagy via the PINK1-dependent pathway
Alghusen, I. M., Carman, M. S., Wilkins, H., Strope, T. A., Gimore, C., Fedosyuk, H., Shawa, J., Ephrame, S. J., Denson, A. R., Wang, X., et al. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1387931 · Cited by 22
“Abnormal mitochondrial function is detected prior to the clinical onset of AD contributing to the progression of the disease (Swerdlow, 2018).”
BackgroundSelf-citationImpact of diet and exercise on mitochondrial quality and mitophagy in Alzheimer's disease
Pradeepkiran, J. A., Islam, M. A., Sehar, U., Reddy, A. P., Vijayan, M., & Reddy, P. H. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102734 · Cited by 27
Gezen‐Ak, D., Alaylıoğlu, M., Genç, G., Şengül, B., Keskin, E., Sordu, P., Güleç, Z. E. K., Apaydın, H., Gurel, C. B., Ulutin, T., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191164 · Cited by 21
Mitochondrial tRNA methylation in Alzheimer’s disease and progressive supranuclear palsy
Silzer, T. K., Pathak, G. A., & Phillips, N. (2020) · BMC Medical Genomics · doi:10.1186/s12920-020-0727-9 · Cited by 24
Mitochondrial pathway polygenic risk scores are associated with Alzheimer's Disease
Paliwal, D., McInerney, T. W., Pa, J., Swerdlow, R. H., Easteal, S., Andrews, S. J., & Initiative, F. T. A. D. N. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.08.005 · Cited by 22
Self-citationIs osteoarthritis a mitochondrial disease?: what is the evidence
Fernández-Moreno, M., Rego‐Pérez, I., & Blanco García, F. J. (2022) · RUC (Universidade Da Coruña) · Cited by 21
Zhang, Z., Wei, D., Li, Z., Guo, H., Wu, Y., & Feng, J. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/9325302 · Cited by 29
“Increasing evidence has demonstrated that hippocampal synaptic mitochondrial impairment is strongly associated with neuronal degeneration in Alzheimer’s disease [11].”
BackgroundHunt, N. J., Wahl, D., Westwood, L. J., Lockwood, G. P., Couteur, D. G. L., & Cogger, V. C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114537 · Cited by 22
“In isolated neurons from patients with LOAD, there is a decline in mitochondrial respiration, reduced NAD+/NADH ratios, diminished glucose uptake, and reduced response to insulin signaling and insulin receptor expression [9,55].”
BackgroundRedox Imbalance in Neurological Disorders in Adults and Children
Rey, F., Berardo, C., Maghraby, E., Mauri, A., Messa, L., Esposito, L., Casili, G., Ottolenghi, S., Bonaventura, E., Cuzzocrea, S., et al. (2023) · Antioxidants · doi:10.3390/antiox12040965 · Cited by 25
Alzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 30
Current Advances in Mitochondrial Targeted Interventions in Alzheimer’s Disease
de Sousa, T. S., Moreira, P. I., & Cardoso, S. (2023) · Biomedicines · doi:10.3390/biomedicines11092331 · Cited by 24
“…Disease: A Brief Overview of the Main Mechanisms The fi rst insights into mitochondria involvement in AD pathology emerged several years ago, when the electron microscopy analysis of the frontal cortex tissue of AD dendrites, Since then, mitochondria-related progression (for a review, see [22]).”
Amyloid-β 25–35 Upregulates Endogenous Neuroprotectant Neuroglobin via NF κ B Activation in vitro
Liu, N., Yu, Z., Xun, Y., Shu, P., Yue, Y., Yuan, S., Jiang, Y., Huang, Z., Yang, X., Feng, X., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180163 · Cited by 23
Rossi, A., Galla, L., Gomiero, C., Zentilin, L., Giacca, M., Giorgio, V., Calí, T., Pozzan, T., Greotti, E., & Pizzo, P. (2021) · Cells · doi:10.3390/cells10020204 · Cited by 22
Hu, Y. R., Xing, S. L., Chen, C., Shen, D. Z., & Chen, J. L. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210608103831 · Cited by 43
Ning, Z., Liu, Y., Wan, M., Zuo, Y., Chen, S., Shi, Z., Xu, Y., Li, H., Ko, H., Zhang, J., et al. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00600-x · Cited by 20
“Emerging evidence suggests a strong connection between mitochondrial dysfunction and AD pathology, potentially playing a synergistic role [52].”
BackgroundZhao, M., Li, J., Li, Z., Yang, D., Wang, D., Sun, Z., Wen, P., Gou, F., Dai, Y., Ji, Y., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179707 · Cited by 27
Mitochondrial microRNAs: Key Drivers in Unraveling Neurodegenerative Diseases
Yashooa, R. K., Duranti, E., Conconi, D., Lavitrano, M., Mustafa, S. A., & Villa, C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020626 · Cited by 22
Mitochondrial fission and fusion in neurodegenerative diseases:Ca2+ signalling
Liu, X., Li, T., Tu, X., Xu, M., & Wang, J. (2025) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2025.103992 · Cited by 24
D’Errico, M., Parlanti, E., Pascucci, B., Filomeni, G., Mastroberardino, P. G., & Dogliotti, E. (2021) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2021.108977 · Cited by 20
He, K., Zhang, J., Zhang, W., Wang, S., Li, D., Ma, X., Wu, X., Chai, X., & Liu, Q. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.772066 · Cited by 22
“Mitochondrial dysfunction is also tightly associated with various cognitive impairment-related disorders, such as Alzheimer’s disease (Swerdlow, 2018), Parkinson’s disease (Macdonald et al., 2018), and diabetes-associated cognitive impairment (Ma et al., 2020).”
BackgroundPhytocannabinoids as Potential Multitargeting Neuroprotectants in Alzheimer’s Disease
Rathod, S., & Agrawal, Y. O. (2023) · Current Drug Research Reviews · doi:10.2174/2589977515666230502104021 · Cited by 21
The Role of Mitochondrial Biogenesis in Ischemic Stroke
Shademan, B., Avcı, Ç. B., Karamad, V., Soureh, G. J., Olia, J. B. H., Esmaily, F., Nourazarian, A., & Nikanfar, M. (2023) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2204088 · Cited by 24
“These findings are supported by in vivo observations of mitochondrial accumulation in AD patients [85,86].”
BackgroundMitochondrial Targeting against Alzheimer’s Disease: Lessons from Hibernation
Mestdagh, C. F. D. V., Smit, A. B., Henning, R. H., & van Kesteren, R. E. (2023) · Cells · doi:10.3390/cells13010012 · Cited by 23
“…torpor (periods of hypothermia and hypometabolism) and arousal (periods when The mitochondrial cascade hypothesis, which originated in 2004 [25], is gaining attention, and by now, a large body of evidence implicates mitochondrial dysfunction as a fundamental causative mechanism in AD [6,26].”
BackgroundExploring the role of mitochondrial proteins as molecular target in Alzheimer’s disease
Chadha, S., Behl, T., Sehgal, A., Kumar, A., & BUNGAU, S. G. (2020) · Mitochondrion · doi:10.1016/j.mito.2020.11.008 · Cited by 20
Shahrivar‐Gargari, M., Hamzeh‐Mivehroud, M., Hemmati, S., Mojarrad, J. S., Notash, B., Küçükkılınç, T. T., Ayazgök, B., & Dastmalchi, S. (2020) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2020.129787 · Cited by 21
Nikseresht, Z., Ahangar, N., Badrikoohi, M., & Babaei, P. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113307 · Cited by 24
Dey, A., Ghosh, S., Rajendran, R. L., Bhuniya, T., Das, P., Bhattacharjee, B., Das, S., Mahajan, A. A., Samant, A., Anand, K., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179690 · Cited by 23
“This is primarily due to neuronal malfunction and cell death caused by the piling up of protein misfolding and interference with intracellular calcium homeostasis [73].”
BackgroundPapadakis, K. A., Doufexi, A., Kalamaki, M. S., Bourazanas, E., & Lymperaki, E. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080384 · Cited by 23
“Furthermore, dysbiotic oral microbiota stimulates the hyperactivity of polymorphonuclear leukocytes (PMNs), leading to increased oxidative stress and excessive production of reactive oxygen species (ROSs), which further exacerbates periodontal tissue destruction [29].”
JM-20 treatment prevents neuronal damage and memory impairment induced by aluminum chloride in rats
Wong-Guerra, M., Montano-Peguero, Y., Ramírez-Sánchez, J., Jiménez-Martín, J., Fonseca-Fonseca, L. A., Hernández-Enseñat, D., Nonose, Y., Valdés, O., Mondelo-Rodríguez, A., Ortiz-Miranda, Y., et al. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.08.017 · Cited by 23
Kessas, K., Chouari, Z., Ghzaiel, I., Zarrouk, A., Ksila, M., Ghrairi, T., Midaoui, A. E., Lizard, G., & Kharoubı, O. (2022) · Cells · doi:10.3390/cells11020257 · Cited by 22
“The main phenomena of AD are: first, the abnormal deposition of amyloid plaques in the extracellular environment of the brain; and second, the dysfunction of the mitochondrial cascade is considered to be the second triggering phenomenon of this disease [67].”
BackgroundEffects of Catalpol on Alzheimer’s Disease and Its Mechanisms
Chen, H., Deng, C., Meng, Z., & Meng, S. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2794243 · Cited by 26
“+e mechanism of Alzheimer’s disease has not yet been fully clarified, but factors such as oxidative stress [2], mitochondrial dysfunction [3], and inflammation [4] play an important role in the occurrence and development of AD.”
BackgroundMitochondrial proteotoxicity: implications and ubiquitin-dependent quality control mechanisms
Karbowski, M., Oshima, Y., & Verhoeven, N. A. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04604-8 · Cited by 23
“While it is still debated whether mitochondrial dysfunctions are early causal events or a consequence of other pathological events in AD patients, many reports showing mitochondrial abnormalities in the brain of AD patients [39, 40, 42, 43] strongly suggest that mitochondrial decline is in the center of AD development.”
BackgroundJia, Y., Wang, W., Han, N., Sun, H.-L., Dong, F., Song, Y., Feng, R.-F., & Wang, J.-H. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.02.076 · Cited by 20
Schork, N. J., Elman, J. A., & Initiative, A. D. N. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230548 · Cited by 25
Liu, X., Zhao, Z., Chen, D., Zhang, Z., Lin, X., Shen, Z., Lin, Q., Fan, K., Wang, Q., Zhang, W., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad562 · Cited by 23
Simple model systems reveal conserved mechanisms of Alzheimer’s disease and related tauopathies
Jiang, Y., & MacNeil, L. T. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00664-x · Cited by 23
“Such dysfunction leads to increased ROS, decreased ATP production and altered ion homeostasis [36, 59, 212, 213, 279, 287].”
BackgroundAnzovino, A., Canepa, E., Alves, M., Lemon, N. L., Carare, R. O., & Fossati, S. (2023) · Cells · doi:10.3390/cells12242840 · Cited by 20
“Indeed, mitochondrial dysfunction and reduced mitochondrial respiratory metabolism have been recognized to be among the earliest and causal events in AD pathogenesis [54,56–65].”
BackgroundVolloch, V., Olsen, B. R., & Rits‐Volloch, S. (2019) · Annals of Integrative Molecular Medicine · doi:10.33597/aimm.02-1006 · Cited by 23
“This is the primary reason for the formulation of the Mitochondrial Cascade Hypothesis [13,14].”
BackgroundImbimbo, B. P., Ippati, S., & Watling, M. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1793755 · Cited by 21
Filippov, M. A., Tatarnikova, O. G., Pozdnyakova, N. V., & Vorobyov, V. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.290878 · Cited by 21
“Genetic abnormalities in mitochondria were demonstrated in the inflammatory bowel disease (Wang et al., 2013; van Tilburg et al., 2014) and mitochondrial dysfunctions were revealed in AD (Moreira et al., 2010; Garcia-Escudero et al., 2013; De Felice and Ferreira, 2014; Swerdlow, 2018).”
BackgroundChen, X., Das, U., Park, G., & Mobley, W. C. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-021-00796-6 · Cited by 20
Fu, J., Zhang, H., Liu, S., Wu, J., Zhang, Y., Gao, Y., Song, F., Qin, Y., Hu, X., & Liu, Z. (2021) · Food & Function · doi:10.1039/d1fo01682b · Cited by 20
Targeted Lipidomics of Mitochondria in a Cellular Alzheimer’s Disease Model
Kurokin, I., Lauer, A. A., Janitschke, D., Winkler, J., Theiss, E. L., Griebsch, L. V., Pilz, S. M., Matschke, V., van der Laan, M., Grimm, H. S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9081062 · Cited by 21
Contributive Role of Hyperglycemia and Hypoglycemia Towards the Development of Alzheimer’s Disease
Chakrabarty, R., Yousuf, S., & Singh, M. P. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02846-y · Cited by 21
“It has been proven to be vital for cellular metabolic processes as well as in the maintenance of equilibrium in metabolic processes [23].”
BackgroundMitochondrial DNA: a molecular switch driving sterile neuroinflammation
Jauhari, A., Singh, T., Carlisle, D. L., & Friedlander, R. M. (2026) · Translational Neurodegeneration · doi:10.1186/s40035-026-00540-w · Cited by 21
“In addition to these hallmark lesions, mitochondrial dysfunction appears early and consistently in AD pathology [147].”
Hyperglycosylation is a metabolic driver of Alzheimer’s disease
Hawkinson, T. R., Liu, Z., Ribas, R. A., Medina, T., Nielsen, R. S., Clarke, H. A., Ma, X., Mueller, A. C., Plasencia, A. F., Sheer, A. L., et al. (2026) · Nature Metabolism · doi:10.1038/s42255-026-01538-4 · Cited by 26
Yang, Z., Subati, T., Kim, K., Murphy, M. B., Dougherty, O. P., Christopher, I. L., Amburg, J. C. V., Woodall, K. K., Barnett, J. V., & Murray, K. T. (2022) · Circulation Arrhythmia and Electrophysiology · doi:10.1161/circep.121.010636 · Cited by 21
Parkin as a Molecular Bridge Linking Alzheimer’s and Parkinson’s Diseases?
Checler, F., & da Costa, C. A. (2022) · Biomolecules · doi:10.3390/biom12040559 · Cited by 19
Butterfield, D. A., Boyd-Kimball, D., & Reed, T. T. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0214 · Cited by 24
“…strategy for AD based on its influence on A b remodeling (Engel et al, 2012; Palhano et al, 2013), tau (Rezai-Zadeh et al, 2008), and reduction of mitochondrial dysfunction (Butterfield and Boyd-Kimball, 2020; Dragi-cevic et al, 2011; Pradeepkiran and Reddy, 2020; Swerdlow, 2018) associated with AD.”
Wang, J., Yu, Z., Ye, P., & Xu, B. (2023) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2023.109397 · Cited by 19
A promising therapeutic: Exosome-mediated mitochondrial transplantation
Cao, M., Zou, J., Shi, M., Zhao, D., Liu, C., Liu, Y., Li, L., & Jiang, H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113104 · Cited by 20
Metadata
- Authors
- Swerdlow, R. H.
- Affiliations
- University of Kansas (US)
- Corresponding author
- Swerdlow, Russell H.
- ORCID
- Swerdlow, Russell H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-07
- Volume
- 62
- Issue
- 3
- Pages
- 1403-1416
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5869994
- OpenAlex
- W2764071986
- Cited by
- 850
- References
- 154
- Citations by year
- 2026: 126 · 2025: 106 · 2024: 97 · 2023: 110 · 2022: 122 · 2021: 114 · 2020: 106 · 2019: 49 · 2018: 18 · 2017: 1
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG035982)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mitochondrial dysfunction
- MeSH terms
- Alzheimer Disease, Animals, Humans, Mitochondria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.